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Dopaminergic Neurons Derived from Human Induced 
Pluripotent Stem Cells Survive and Integrate 
into 6-OHDA-Lesioned Rats
Jingli Cai,1 Ming Yang,1 Elizabeth Poremsky,1 Sarah Kidd,2 Jay S. Schneider,2 and Lorraine Iacovitti1
Cell replacement therapy could be an important treatment strategy for Parkinson’s disease (PD), which is caused 
by the degeneration of dopamine neurons in the midbrain (mDA). The success of this approach greatly relies 
on the discovery of an abundant source of cells capable of mDAergic function in the brain. With the paucity of 
available human fetal tissue, efforts have increasingly focused on renewable stem cells. Human induced plurip-
otent stem (hiPS) cells offer great promise in this regard. If hiPS cells can be differentiated into authentic mDA 
neuron, hiPS could provide a potential autologous source of transplant tissue when generated from PD patients, 
a clear advantage over human embryonic stem (hES) cells. Here, we report that mDA neurons can be derived 
from a commercially available hiPS cell line, IMR90 clone 4, using a modifi ed hES differentiation protocol estab-
lished in our lab. These cells express all the markers (Lmx1a, Aldh1a1, TH, TrkB), follow the same mDA lineage 
pathway as H9 hES cells, and have similar expression levels of DA and DOPAC. Moreover, when hiPS mDA 
progenitor cells are transplanted into 6-OHDA-lesioned PD rats, they survive long term and many develop into 
bona fi de mDA neurons. Despite their differentiation and integration into the brain, many Nestin+ tumor-like 
cells remain at the site of the graft. Our data suggest that as with hES cells, selecting the appropriate population 
of mDA lineage cells and eliminating actively dividing hiPS cells before transplantation will be critical for the 
future success of hiPS cell replacement therapy in PD patients.
Introduction
Currently there is no cure for PD patients, though some pharmaceutical or surgical treatments may alle-
viate symptoms at early stages. In most cases, however, se-
rious side effects and other PD-related complications appear 
as the disease progresses. Consequently, cell-based therapy, 
particularly in late stage disease, remains a promising 
approach. Cell replacement is especially attractive in PD be-
cause neurodegeneration is largely confi ned to one nucleus, 
the substantia nigra (SN), which is comprised exclusively of 
midbrain dopamine (mDA) neurons. Finding a reliable and 
abundant cell source capable of mDAergic function in the 
brain is therefore vital for the success of this therapy. With 
the paucity of available human fetal tissue, efforts have in-
creasingly focused on renewable cells such as human neural 
progenitor cells (hNPs). Over the past decade, much pro-
gress has been made in defi ning the parameters in culture 
that promotes the appearance of mDA traits in hNPs derived 
from any of a number of embryonic and adult tissues [1,2]. 
Our own studies have shown that hNPs derived from clonal 
lines [3–5], embryonic cerebral cortex [6], adult human bone 
marrow [7,8], amniotic fl uid [9], and hES cells [10,11] can be 
induced to express mDA traits by modifying their growth 
conditions in culture. However, only those hNPs derived 
from pluripotent cells such as human embryonic stem (hES) 
cells actually survive and give rise to midbrain-specifi c DA 
(mDA) neurons following transplantation in vivo.
Capitalizing on the advances in somatic cell nuclear 
transfer technology and fueled by a greater understanding 
of ES cell pluripotency, several seminal studies have now 
shown that somatic cells can be re-programmed to become 
pluripotent stem cells, termed induced pluripotent stem (iPS) 
cells, following the transfection of several key transcrip-
tion factors, including Oct4 and Sox2, into mouse or human 
fi broblasts [12–14]. The emergence of iPS cell technology has 
prompted a plethora of new studies. Of relevance to PD is 
the recent study by Wernig et al. [15] showing that iPS cells 
generated from mouse fi broblasts can be differentiated in 
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immunofl uorescence staining method described previously 
[6]. Cultures or sections were stained with rabbit antibod-
ies to Lmx1a (kind gift of Dr. M. German, UCSF); rabbit 
anti-Nestin from Millipore AB5922, 1:200; mouse anti-Sox2 
from R&D Systems MAB2018, 1:1,000; mouse anti-TrkB from 
R&D Systems MAB397, 1:100; rabbit anti-TH from Pel-Freez 
P40101–0, 1:200 or sheep anti-TH from Abcam AB113, 1:1,000; 
Goat anti-Aldh1a1 from Novus Biologicals NB100–2563, 1:200; 
mouse anti-nuclear human specifi c (HNA) from Millipore 
MAB1281 at 1:40; rabbit anti-Ki67 from Abcam AB833 at 1:50. 
All secondary antibodies were Alexa Fluor antibodies from 
Invitrogen used at 1:200. Cultures or sections were mounted 
in ProLong Gold antifade reagent (Invitrogen, Carlsbad, 
CA) and analyzed using a Nikon-Scanalytics Image System 
or an Olympus IX81 Image System. Confocal analysis was 
performed using a laser scanning confocal microscope 
(Olympus Fluoview, Olympus America Inc.).
RNA isolation and CDNA synthesis
Total RNA was isolated directly from freshly collected 
Stg IV and Stg V hiPS cells with TRIzol LS (Invitrogen), a 
modifi cation of the guanidine isothiocyanate-phenol-chlo-
roform extraction method. cDNA was synthesized by using 
100 ng total RNA in a 20 μL reaction with Superscript III 
(Invitrogen) and oligo(dT)12–18 (Invitrogen). One microliter 
of RNase H (Invitrogen) was added to each reaction tube, 
and the tubes were incubated for 20 min at 37°C before pro-
ceeding to PCR.
PCR amplifi cation
A 0.5 μL cDNA template was used in a 20 μL reaction 
volume with the PCR master mix (Promega, Madison, WI). 
The cycling parameters were: 94°C, 30 s; 55°C, 30 s; 72°C, 30 
s, for 30 cycles. The PCR cycles were preceded by an initial 
denaturation of 3 min at 94°C and followed by a fi nal exten-
sion of 10 min at 72°C. Primers are listed in Table 1 (CHAT 
primers were found in [17]).
Detection of dopamine and metabolite
Dopamine and metabolite levels were measured using high 
pressure liquid chromatography (HPLC) with electrochem-
ical detection (Coulochem III system; ESA Inc., Chelmsford, 
MA). Cells from 2 different batches were sonicated in 0.4 M 
perchloric acid, the homogenate was centrifuged at 14,000 
rpm for 10 min, and the supernatant was removed for 
analysis. Dopamine and metabolites were separated by injec-
tion of sample onto a C18 solid phase extraction column (ESA 
Inc.). The mobile phase consisted of 75 mM sodium dihydro-
gen phosphate, 1.7 mM 1-octanesulfonic acid, 100 μL/L tri-
ethylamine, 25 μM EDTA, and 10% acetonitrile. Peak heights 
of known external standards were used to create a standard 
curve to quantify dopamine and metabolite levels in each 
sample (EZChrome Chromatography Software, Scientifi c 
Software Inc., San Ramon, CA). Protein was extracted from 
the remaining cell pellet (NE-PER®, Pierce, Rockford, IL) 
and cytoplasmic protein levels were measured using a bicin-
choninic acid (BCA) reaction (Pierce, Rockford, IL). Final do-
pamine and metabolite levels were then corrected based on 
the amount of protein in each sample.
culture and transplanted into PD rats to produce motor re-
covery. These studies, taken together with the recent dem-
onstration that human iPS (hiPS) cells can be generated 
directly from PD patients [16], offer hope that patients may 
someday supply their own replacement mDA neurons.
In recent months, Wicell has made available lines of hiPS 
cells, including a clone (IMR90, clone 4) that behaves nearly 
identically to the H9 hES cell line [14]. Here, we report that 
we can generate mDA neurons from this hiPS line at a sim-
ilar effi ciency as with H9 hES cell line. The mDA precursor 
cells were also injected into the striatum of 6-OHDA-lesioned 
rat PD models and mature DA neurons were found 6 weeks 
after transplantation. Our data suggested that this hiPS cell 
line can now be used in proof of principle experiments to 
study the genes and mechanisms that promote the mDA dif-
ferentiation of hiPS cells in culture and factors that enhance 
their survival and function after their transplantation into 
the PD rat brain. In addition, these studies can provide the 
critical validation needed before hiPS cells, even those gen-
erated directly from patients can be fully embraced for use 
in PD.
Materials and Methods
Tissue culture
hiPS cells (IMR90, clone 4) were purchased from Wicell 
Research Institute (University of Wisconsin-Madison, 
Madison, WI) who generate the cell line through viral 
infection [14] and maintained according to the supplier’s 
instructions. In brief, cells were grown on a monolayer of 
primary mouse fi broblasts (MEFs; Millipore #PMEF-CF) in 
DMEM/F12 media (Invitrogen #11330) supplemented with 
20% Knockout Serum Replacer™ (KOSR; Invitrogen #10828), 
1% nonessential amino acids (Invitrogen #11140), 1 mM 
l-glutamine (Invitrogen #25030), 0.1 mM 2-mercaptoetha-
nol, and 100 ng/mL bFGF (R&D systems,Minneapolis, MN, 
#233-FB/CF). Cell propagation was achieved through man-
ual dissection and transfer of cell colonies once per week 
(Stg I). The differentiation process was initiated with the 
formation of embryoid bodies (EBs, Stg II, 4 days). Rosettes 
of hNPs were generated on Geltrex (Invitrogen #A10480)-
coated tissue culture plates in NEP basal medium consist-
ing of DMEM/F12 (Invitrogen #11320), 1 mg/mL BSA (Sigma 
#A2153), 1× N2 supplements (Invitrogen #17502), 1× B27 
supplements (Invitrogen #17504), and 1% Pen-strep (Stg III, 
4 days). Rosettes were then expanded in NEP basal medium 
supplemented with 20 ng/mL bFGF every 2 days (Stg IV, 7 
days). After 1 week, rosettes were lifted, seeded onto Ultra-
low dishes, and carried for 1–3 weeks as NP spheres before 
further differentiation in culture or transplantation into the 
brain. For further differentiation down the DA pathway, 
cells were seeded onto Geltrex-coated slides and incubating 
for 1 week in 1 mM dibutyryl cAMP (dbcAMP; Sigma, St. 
Louis, MO), as described in [10] (Stg V, 7 days).
Immunocytochemistry
Cultures were rinsed twice and then fi xed with 4% para-
formaldehyde as previously detailed [10]. Transplanted rat 
brains were perfused with 4% cold (4°C) periodate–lysine–
paraformaldehyde, sectioned at 30 μm on a freezing micro-
tome, and processed for immunocytochemistry using the 
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 T able 1.  PCR Amplification Primers 
Gene names Primer location Sequence Product size (bp)
Aldh1a1 Sense GCTTATCAGCAGGAGTGTTTACCA 150
Antisense CTCTTCCATTTCCAGACATCTTGA
CHAT* Sense ATCGCTGGTACGACAAGTCC 151
Antisense ATCAGCTTCCTGCTGCTCTG 
DBH Sense CCACTGGTGATAGAAGGACGAAA 120
Antisense GGCCATCACTGGCGTGTAC
Foxa2 Sense AGGAGGAAAACGGGAAAGAATATAA 150
Antisense AAGTAAGACTTCCCTGCAACAACA
GAD67 Sense ATTCTTGAAGCCAAACAG 617
Antisense TAGCTTTTCCCGTCGTTG
GAPDH Sense GGAGTCAACGGATTTGGTCGTA 150
Antisense GAATTTGCCATGGGTGGAAT
GLAST Sense GGCTTACTCATTCACGCAGTCA 140
Antisense GGTAGGGTGGCAGAACTTGAAG
Lmx1a Sense CAGCCTCAGACTCAGGTAAAAGTG 150
Antisense TGAATGCTCGCCTCTGTTGA
Msx1 Sense CTCCCTGAGTTCACTCTCCG 192
Antisense CAGGAGACATGGCCTCTAGC
Nurrr1 Sense GGCTGAAGCCATGCCTTGT 150
Antisense GTGAGGTCCATGCTAAACTTGACA
Pitx3 Sense GGACTAGGCCCTACACACAGA 151
Antisense TCCGCGCACGTTTATTTC
TH Sense GCACCTTCGCGCAGTTCT 107
Antisense CCCGAACTCCACCGTGAA
TPH1 Sense TCTATACCCCAGAGCCAGATACCT 150
Antisense AGTAGCACGTTGCCAGTTTTTG
Results
Human iPS cells behave and differentiate into mDA 
neurons similarly as HES cells in vitro
Human iPS cells (IMR90, clone 4) were expanded accord-
ing to the manufacturer’s instruction. When supplemented 
with 100 ng/mL bFGF, hiPS colonies displayed distinct 
smooth boundaries, which showed that cells were in the 
undifferentiated condition (Fig. 1A). Undifferentiated hiPS 
cells (Stg I) were differentiated further (Stg II to Stg V) using 
a modifi ed 5-stages DA differentiation protocol developed 
in the lab as detailed in [10]. These 5 stages of the mDA dif-
ferentiation process are: Stg I undifferentiated stem cells; 
Stg II embryonic bodies: Stg III hNPs forming; Stg IV hNPs 
expansion; and Stg V mDA neuron maturation. As shown 
in Figure 1B, undifferentiated hiPS cells could be lifted and 
made into EBs in a very similar way as hES cells. When EBs 
were replated on Geltrex-coated dishes with NEP basal me-
dium, cells were further differentiated into Stg III hNPs (Fig. 
1C). Occasionally rosette-like structures were observed (Fig. 
1C, arrow and inset).
By tracking transcription factor Lmx1a and other cell 
type (Aldh1a1, TH, TrkB), and stage (Sox2, Nestin)-specifi c 
markers, we have delineated individual steps in the mDA 
fate restriction process as hES cells transition from unspeci-
fi ed hNPs (Aldh1a1+/Lmx1a−) to mDA-specifi ed NPS (mDA-
NPs, Aldh1a1+/Lmx1a+) to mDA-specifi ed precursors 
(mDA-PCs) to differentiated mDA neurons (Aldh1a1+/TH+).
6-OHDA lesions
As described previously [10], 9 Fischer 344 rats (Taconic) 
were made Parkinsonian for these studies. In brief, rats were 
anesthetized with sodium pentobarbital (30 mg/kg i.p.) and 
placed in a stereotaxic apparatus (Kopf Instruments), and a 
26-gauge Hamilton syringe containing 6-OHDA (Sigma; 20 
μg/mL in 4 μL PBS containing 0.2 mg/mL ascorbate) was 
lowered into the right median forebrain bundle (AP: −4.4 
mm, ML: −1.2 mm, DV: −7.8 mm from bregma). The 6-OHDA 
solution was gradually injected at a rate of 1 μL/min. All 
lesions were verifi ed 3 and 6 weeks later by assessment 
of rotational behavior in an automated rotometer system 
(Columbus Instruments) following amphetamine challenge 
(5 mg/kg, i.p.). Only rats with consistent and stable lesions 
(>10 ipsilateral turns/min on multiple tests) were used for 
transplantation studies.
Transplantation procedures
Animals with verifi able lesions (>10 ipsilateral turns/
min) were implanted with a total of 10 μL of HBSS contain-
ing approximately 1 × 106 stage IV hiPS cells, deposited at 3 
stereotaxic levels (AP: +1.2 mm, ML: −2.7 mm, DV: −5.4 mm, 
–4.9 mm and −4.2 mm) in the striatum on the side ipsilateral 
to the 6-OHDA lesion as described previously [10]. All trans-
plant recipients received cyclosporin A (15 mg/kg IP) daily, 
beginning 1–2 days before transplantation. Animals were 
sacrifi ced at 6 weeks (N = 3).
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neurons were found in our Stg V hiPS cells when synthetic 
enzymes specifi c for these neurotransmitters (CHAT, DBH, 
GAD67, and TPH1, respectively) were examined. The ex-
pression patterns of these iPS genes were equivalent to Stg V 
cells of H9 hES cell origin (Fig. 3E).
Using HPLC, we also detected DA and its metabolite 
DOPAC in hiPS Stg V cells (Fig. 3F). While DA and DOPAC 
levels in undifferentiated cells (0.91, 17.32 pmoles/mg pro-
tein) were similar to those of other negative control cell lines 
(such as B35), hiPS Stg V cells expressed much higher lev-
els of DA and DOPAC (7.31 ± 2.79, 357.94 ± 189.19 pmoles/
mg protein) indicating that functional DA neurons were 
differentiated from hiPS cells (The DA level of our positive 
control SK-N-SH cells is around 3.0 pmoles/mg protein). 
Interestingly, H9 Stg V cells had comparable levels (8.18 ± 
0.26, 283.78 ± 40.37 pmoles/mg protein) to hiPS Stg V cells, 
which is another characteristic shared by hES cells and 
hiPS cells.
Partially differentiated hiPS cells survive and give 
rise to mDA neurons after transplantation 
into a PD rat model
We next examined whether hiPS cells followed the same 
mDA differentiation process after their transplantation into 
the 6-OHDA-lesioned rat striatum. Cells were harvested at 
At Stg IV, hNPs labeled with Nestin and Sox2 (Fig. 2A 
and 2D) were further expanded in the NEP basal medium 
supplemented with bFGF. Compared to Stg III cells, many 
more rosettes of Nestin+Sox2+ hNPs were formed at Stg IV 
(Fig. 2A and 2D), which also expressed mDA-specifi ed hNPs 
markers Lmx1a and Aldh1a1 (Fig. 2B and 2E, arrowheads). 
Non-specifi ed Aldh1a1+ only hNPs were also found outside 
cell aggregates (Fig. 2B and 2E, arrows). As with hES cells, 
mDA-specifi ed hiPS cells also expressed TrkB on their sur-
face (Fig. 2C and 2F).
With the addition of 1 mM cAMP in Stage V, cells fur-
ther differentiated into Aldh1a1+/TH+ mDA neurons (Fig. 
3A and 3B). As with hES cells, even in terminally differenti-
ated Stg V hiPS cultures, cells at earlier (Lmx1a+/Aldh1a1+) 
steps in the mDA differentiation process continued to be 
present (Fig. 3C). The yield of TH+ cells in total cells, 6.5% ± 
1.4%, was also similar to that of hES cells. As expected, these 
mDA neurons did not co-label with GABA (data not shown). 
Corroborating our immunocytochemical fi ndings, the mDA 
lineage markers Lmx1a, Msx1, Foxa2, Pitx3, Aldh1a1, Nurr1, 
and TH were all detected in later differentiation stages (IV, 
V) by RT-PCR (Fig. 3D). Meanwhile, RT-PCR analysis also 
identifi ed that Stg V hiPS cells contained other neurotrans-
mitter types, particularly glutamatergic neurons express-
ing the glutamate transporter gene (GLAST). However, very 
few cholinergic, noradrenergic, GABAergic, or serotonergic 
FIG. 2. Expression of neural markers at Stg IV of human-induced pluripotent stem (hiPS) cells. (A) Neural progenitor 
markers Nestin (red) and Sox2 (green) were detected in many Stg IV hiPS cells, including cells inside rosettes. (B) Dopamine 
neurons in the midbrain (mDA) lineage markers Aldh1a1 and Lmx1a were expressed in Stg IV hiPS cells. Notice that there 
were 2 types of Aldh1a1 expressing cells: one was with long processes and inside rosettes or aggregates (arrowhead), the 
other was fl at and outside aggregates (arrow). (C) Similar to human embryonic stem (hES) cells, mDA-specifi ed hiPS cells 
labeled by Lmx1a also expressed TrkB on their surface. Dapi was used to counterstain all the nuclei in the fi eld (A–C). Scale 
bar = 50 μm for A–C. (D–F) Higher magnifi cation confocal images of A–C, respectively.
FIG. 1. Bright fi eld pictures of (A) undiffer-
entiated human-induced pluripotent stem 
(hiPS) cells (Stg I), (B) embryonic bodies (Stg 
II), and (C) neural differentiating hiPS cells 
(Stg III). The arrow in C indicates rosettes 
observed in Stg III cells (inset). Scale bar = 
100 μm for A and C, 250 μm for B.
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host origin were also detected (Fig. 4B). Within the grafts, a 
subset of cells are mDA-specifi ed, including Lmx1a+/Aldh+ 
mDA-NPs and Lmx1a-/Aldh+ mDA precursor cells (Fig. 
4D). In addition, we found many differentiated Aldh1a1+/
TH+ mDA neurons (Fig. 4E and 4F) that elicited long com-
plex processes and appeared be well integrated into the pa-
renchyma of the brain. As with hES cells grafts, however, 
stage IV and transplanted as described previously [11]. When 
grafts were analyzed 6 weeks post-transplantation, we again 
found cells at all stages in the DA fate restriction process (Fig. 
4). Thus, the grafts contained abundant hiPS cells identifi ed 
by the presence of the human nuclear antigen (HNA, Fig. 4A 
and 4B) and the stem cell markers Nestin (Fig. 4A) or Sox2 
(Fig. 4B). In addition, Sox2+/HNA− neural progenitor cells of 
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FIG. 3. RT-PCR and immunocytochem-
ical analyses of DA-related markers in late 
stages of human-induced pluripotent stem 
(hiPS) cells differentiation in culture. Many 
Aldh1a1+/TH+ dopamine neurons in the 
midbrain (mDA) neurons [(A) fl uorescent 
microscope image, (B) confocal microscope 
image] and some Lmx1a+/Aldh1a1+ earlier 
step cells in the mDA differentiation (C) were 
observed at Stg V. Dapi was used to counter-
stain all the nuclei in the fi eld. The yield of 
TH+ expressing cells in Stg V-differentiated 
hiPS cells is similar as hES cells. Scale bar 
= 50 μm for A and C. (D) DA-related genes 
are differentially expressed at stages IV–V 
of hiPS cell differentiation detecting by 
RT-PCR. (E) StgV of both H9 and hiPS cells 
express GLAST, but not other neurotrans-
mitter system genes. (F) Signifi cantly higher 
levels of DA and DOPAC were detected in 
Stg V hiPS cells and H9 cells as well.
FIG. 4. Immunofl uorescence analysis of DA-related markers in stage IV human-induced pluripotent stem (hiPS) cells 
6 weeks after transplantation. Most survived transplanted cells in the graft as detected by human nuclear antigen (HNA) 
are Nestin+ neural progenitor cells (A). Some are still Sox2+ neural progenitor cells (B). Occasionally proliferating Ki67 cells 
were found in the HNA+ grafted cells (C). Arrowhead pointed area is shown at a higher magnifi cation in the inset. Clusters 
of Lmx1a+/Aldh1a1+, Aldh1a1+ precursor cells (D) were found in the grafts. Insets of D show the majority of these DA 
precursor cells were HNA+. Mature TH+/Aldh1a1+ neurons were also detected (E and F). Inset of E shows a grafted TH+/
HNA+ neuron was surrounded by host cells (HNA−). Scale bar = 50 μm.
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techniques are being refi ned, it is important that the stem cell 
fi eld have access to a reliable commercially available hiPS 
cell line that can be used to continue to study basic biological 
questions pertaining to these cells and their potential uses. 
In the PD research area, for instance, the Wicell clone can be 
used to effectively and effi ciently develop mDA differenti-
ation methods, to identify markers of mDA differentiation 
stages, to select appropriate mDA cells for transplantations, 
and to optimize transplantation protocols.
Challenges remaining in hiPS application for cell 
replacement therapy in PD
Similar to hES cells, the transplantation of differentiated 
hiPS cells into a rat model of PD resulted in continued cell 
heterogeneity in the graft as well as unchecked cell prolif-
eration. In our transplantation experiment, a large number 
of Nestin+ precursor cells existed together with mDA neu-
rons inside the grafts. These undifferentiated cells pos-
sessed the potential to continue dividing and to give rise 
not only to more mDA neurons but also to many other cell 
types, some of which formed teratoma-like structures. This 
phenomenon makes the pre-selection of mDA lineage-re-
stricted late precursor cells critical for the future success 
of this clinical application. Although we now know a great 
deal about the transcription machinery involved in mDA 
differentiation process (reviewed in ref. [21–23]), unfortu-
nately there are still no good cell surface markers specifi c 
for mDA precursor population that allow for their precise 
selection. Further characterization of mDA lineage cells 
will be extremely important in this regard and the avail-
ability of hiPS cell line IMR90 clone 4 will be very useful in 
such studies.
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cells were differentiated into mDA neurons using the same 
conditions as those described for hES cells [11], they fol-
lowed an analogous differentiation pathway: forming EBs, 
neural differentiation, neural progenitor proliferation and 
specifi cation, and mDA neuron development. As detected 
by either RT-PCR or immunocytochemistry, at each stage 
they also expressed markers typical of their mDA pheno-
type (Lmx1a+ Aldh1a1+ mDA-specifi ed hNPs, Aldh1a1+ 
mDA precursors, Aldh1a1+TH+ mDA neurons) and not 
other (GABAergic, cholinergic, noradrenalinergic, seroto-
nergic) neurotransmitter systems. In addition, these differ-
entiated hiPS cells also manufacture measurable levels of 
DA and its metabolite DOPAC. When Stg IV neural progeni-
tors/precursors were transplanted into 6-OHDA-lesioned 
PD rat models, differentiated hiPS cells survived and inte-
grated into host striatum and continued their mDA devel-
opment into differentiated Aldh1a1+TH+ mDA neurons. 
Our data confi rm that hiPS cells, similar to hES cells, can 
serve as another potential cell source of authentic mDA neu-
rons for cell replacement therapy in PD patients. Moreover, 
once procedures for generating hiPS cells from a patient’s 
own somatic cells become standardized, it will be possible 
to generate autologous mDA neurons for transplantation, 
overcoming one of the greatest obstacles, immunorejection, 
facing the hES cell fi eld.
Human iPS cell line IMR90 clone 4 as a standard 
model for basic research
Since the discovery of iPS technology several years ago, 
many groups have tried to optimize reprogramming proce-
dures to more effi ciently produce safer iPS cell lines. For ex-
ample, a number of procedures have been developed using 
different combinations of transcription factors in an effort 
to eliminate the introduction of oncogene c-Myc [14,18]. In 
addition, nonintegrating adenovirus vectors [19] or excisable 
viruses [16] have been used to transiently express stemness 
genes. More recently, protein cocktails have been devel-
oped to avoid viral vectors all together [20]. While these new 
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